Bookrunner Canaccord Genuity and co-manager Maxim Group will assist
By Devika Patel
Knoxville, Tenn., Nov. 20 - Aeterna Zentaris Inc. said it priced a $15.07 million public offering of units. The offering was announced Tuesday.
The company will sell 13.1 million units of one common share and a warrant at $1.15 per unit. Each whole warrant will be exercisable at $1.60 for five years. The strike price is a 0.63% premium to the Nov. 19 closing share price of $1.59.
Canaccord Genuity Inc. is the bookrunning manager.
Settlement is expected Nov. 25.
Proceeds will be used for drug development activities, future negative cash flow, general corporate purposes and working capital.
Aeterna Zentaris is an oncology and endocrinology drug development company based in Québec City.
| Issuer: | Aeterna Zentaris Inc.
|
| Issue: | Units of one common share and a warrant
|
| Amount: | $15,065,000
|
| Units: | 13.1 million
|
| Price: | $1.15
|
| Warrants: | One warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $1.60
|
| Bookrunner: | Canaccord Genuity Inc.
|
| Co-manager: | Maxim Group LLC
|
| Announcement date: | Nov. 19
|
| Pricing date: | Nov. 20
|
| Settlement date: | Nov. 25
|
| Stock symbol: | Nasdaq: AEZS
|
| Stock price: | $1.59 at close Nov. 19
|
| Market capitalization: | $32.35 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
